Ventrix

What Ventrix does

Ventrix is a privately held, for-profit biotechnology company headquartered in San Diego, California, founded in 2009. The company is developing a new class of Extracellular Matrix (ECM) bioTherapeutics — biomaterial scaffolds that leverage the natural structural and biochemical properties of ECM to guide tissue repair and regeneration. Its primary stated application is cardiac repair, addressing patients whose tissue repair is stalled because functional ECM can no longer support normal cellular processes.

The company's core technology is rooted in the biology of native ECM: a tissue-specific network of macromolecules that provides architectural structure and biochemical cues influencing cell proliferation, differentiation, survival, and function. Ventrix's stated value proposition is to translate the beneficial properties of native ECM into a therapeutic modality that prompts the body to regenerate healthy tissue microenvironments. The company identifies tissue repair and regeneration as its primary use-case segment and adopts a horizontal segmentation approach across indications that could benefit from ECM-guided intervention. Scientific leadership traces to co-founder Karen Christman, with executive leadership including co-founder and CEO Adam Kinsey and Chief Medical Officer Paul Chamberlin.

Ventrix operates with 11-50 employees and remains pre-commercial. The input data does not disclose named products, pricing, customer logos, marketing or distribution channels, partnerships, regulatory milestones, or patent grants beyond the company's broad technology positioning. Capital formation to date is documented across two early-stage financings totaling approximately $5.3 million (a 2010 round of $147,000 and a 2012 round of approximately $5.16 million), with investors and lead investors undisclosed. The website remains active, and operating status is indicated as continuing, but the absence of any disclosed revenue, pricing, or recent commercial activity places the company firmly in the research-and-translational development phase.

Name

Ventrix

Website

https://ventrixbio.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Ventrix is a privately held San Diego biotech developing Extracellular Matrix (ECM) bioTherapeutics — biomaterial scaffolds that harness native ECM properties to guide cardiac tissue repair and regeneration, serving patients whose tissue repair is stalled due to loss of functional ECM support.

Ownership category

akta.pro rank

Product category

Cardiac Regenerative Medicine

akta.pro primary industry

Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

Keywords

• Cardiac repair biomaterials
• Extracellular matrix therapeutics
• Regenerative medicine scaffolds
• Tissue engineering therapeutics
• Biomaterial cardiac therapy

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Ventrix is developing a new class of ECM (Extracellular Matrix) bioTherapeutics — biomaterial scaffolds that leverage the natural scaffolding and biochemical signaling properties of native extracellular matrix to guide the body to repair damaged tissue and generate a new healthy microenvironment, with a lead focus on cardiac repair. The company positions itself as a leader in ECM bioTherapeutics, targeting patients whose tissue repair is stalled due to non-functional ECM.

Product overview

Ventrix is developing a new class of ECM (Extracellular Matrix) bioTherapeutics. The company is focused on creating biotherapeutics that leverage the natural scaffolding properties of extracellular matrix to guide the body's repair mechanisms and generate new healthy microenvironments and tissue. No specific named products or modules are currently identified in available source materials.

Differentiator

Problem solved

Functional benefit

Products and services

• ECM bioTherapeutics (cardiac repair biomaterial scaffold) A class of biotherapeutics built from extracellular matrix biomaterial scaffolds intended to guide the body to repair and regenerate healthy cardiac tissue, targeting patients whose tissue repair is stalled due to non-functional ECM.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights2 records

Direct peers

• Humacyte: Humacyte develops bioengineered, decellularized tissue substitutes and regenerative vessels using proprietary manufacturing platforms. Like Ventrix, it operates in the regenerative medicine/biologic scaffold space and pursues vascular and cardiovascular applications, making its business model and regulatory pathway closely comparable.
• CorMatrix Cardiovascular (Lifenet Health): CorMatrix developed and commercialized acellular ECM-based biomaterials for cardiac and vascular tissue repair before being folded into LifeNet Health. It is the most direct historical analog to Ventrix's ECM-scaffold approach for cardiac applications.
• Mesoblast: Mesoblast is a late-stage regenerative medicine company developing cellular therapies for chronic heart failure and inflammatory conditions. It competes for the same physician audience and biopharma partnership dollars as Ventrix in cardiac regenerative medicine.
• Capricor Therapeutics: Capricor develops cell-based therapies for Duchenne muscular dystrophy and cardiac indications, including exosome and cardiosphere-derived cell platforms. It directly overlaps with Ventrix in pursuing regenerative mechanisms for damaged cardiac tissue.
• CollPlant Biotechnologies: CollPlant develops bioengineered human recombinant collagen and tissue repair products, including in cardiac and soft-tissue repair. Its technology and target clinical applications overlap with Ventrix's ECM-based approach to regenerative scaffolds.
• Athersys: Athersys (now part of Helius Medical) develops stem-cell-based MultiStem therapies, including for acute myocardial infarction. It is a directly comparable regenerative medicine platform addressing cardiac indications with a biologic mechanism.
• Acell: Acell commercializes extracellular matrix-based wound care and surgical repair products derived from porcine urinary bladder. Its ECM platform and tissue-regeneration use cases are closely aligned with Ventrix's core technology positioning.

Broad incumbents

• MiMedx Group: MiMedx markets amniotic membrane and placental tissue ECM products for wound healing, surgical repair, and regenerative applications. It is a larger, established player in the broader ECM/biologic regenerative space relevant to Ventrix's category.
• LifeNet Health: LifeNet Health is a leading allograft and tissue banking organization that, via CorMatrix, supplies cardiac ECM patches used in surgical repair. It serves as both a potential partner and a broader incumbent in the cardiac ECM and regenerative tissue space relevant to Ventrix.

Emerging players

• Xeltis: Xeltis develops bioabsorbable, regenerative vascular grafts intended to enable endogenous tissue restoration. While focused on vascular rather than myocardial repair, it shares Ventrix's tissue-engineering scaffold philosophy and cardiovascular target market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights4 records

Customer concentration

• Xx.com/ventrixheart
• Facebookfacebook.com/VentrixHeart
• LinkedInlinkedin.com/company/ventrix

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ventrix